Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors - Seite 2
Merus is currently enrolling patients on the Phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancers. The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors. Further details, including current trial sites, can be found at www.ClinicalTrials.gov and Merus’ trial website at www.nrg1.com or by calling 1-833-NRG-1234.
About NRG1 Fusions
The NRG1 gene encodes neuregulin (also known as heregulin), the ligand for HER3. Fusions between NRG1 and partner genes are rare, tumorigenic genomic events occurring in patients with certain
cancers.
About Patient Finding Programs
myTomorrows is committed to making drug development serve everyone better. This is done by engaging with both patients and their physicians to gain insights into needs
and outcomes within the context of the pre-approval landscape. With these established relationships myTomorrows is very well positioned to assist bio-pharma companies of all sizes in their
efforts to identify, engage with and offer patients the opportunity to participate in clinical research. In parallel to online activities such as disease awareness campaigns, myTomorrows also
addresses physician-related barriers to Clinical Trial participation by acting as their trusted partner in information provision and proactive assistance with eligibility assessments as well as
enrollment procedures.
Lesen Sie auch
About myTomorrows
myTomorrows operates as an integrated end-to-end platform serving patients, healthcare providers, and drug developers. myTomorrows offers direct support as a single point of contact for patients
with a life-threatening disease where there are limited or no standard approved therapies. These patients and their physicians are provided a personalized report detailing relevant Clinical Trials
and pre-approval treatment options. myTomorrows also serves as a global partner for companies developing drugs to treat patients with unmet medical needs through program management at all phases,
from patient identification for Clinical Trials to the distribution of investigational drugs around the world.